Leonard Green & Partners’s BriaCell Therapeutics BCTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
– Sell
-3,333
Closed -$5.07M – 17
2022
Q1
$5.07M Buy
+3,333
New +$3.94M 0.03% 41

Other funds holding BCTX

Leonard Green & Partners's BCTX Position: Q2 2022 in Review

Leonard Green & Partners sold out of BriaCell Therapeutics (BCTX) in Q2 2022, closing a stake of 3,333 shares — an estimated $5.07M sold.

Leonard Green & Partners first reported a position in BCTX in Q1 2022 and held it in 1 quarter. The position peaked at $5.07M in Q1 2022. 20 funds tracked by Wall St. Rank hold BCTX as of Q2 2022.

  • Leonard Green & Partners reported no remaining BriaCell Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Leonard Green & Partners sold 3,333 BriaCell Therapeutics shares in Q2 2022, an estimated $5.07M.
  • Leonard Green & Partners first reported a position in BriaCell Therapeutics in Q1 2022 and held it in 1 quarter.
  • Leonard Green & Partners's BriaCell Therapeutics position peaked at $5.07M in Q1 2022.
  • 20 funds tracked by Wall St. Rank held BriaCell Therapeutics as of Q2 2022.

Based on Leonard Green & Partners's 13F filing for Q2 2022, filed 15 Aug 2022.